BCG Immunotherapy Altered CNS Immunity and Alzheimer’s Biomarkers
TL;DR: A 2026 open-label study in Communications Medicine found that Bacillus Calmette-Guerin (BCG) immunotherapy changed cerebrospinal-fluid immune-cell responses and Alzheimer-related biomarkers in 23 older adults. Key Findings Small trial context: 2 related 1-year open-label trials enrolled 23 adults aged 55 or older at one academic medical center. BCG dosing was simple: Participants received 2 intradermal …
